Analysts Set Cardlytics, Inc. (NASDAQ:CDLX) PT at $6.92

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have earned an average rating of “Hold” from the seven research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.92.

Several equities research analysts have recently issued reports on CDLX shares. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Evercore ISI initiated coverage on shares of Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Bank of America downgraded shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $4.00 to $3.50 in a report on Thursday, August 15th.

Cardlytics Trading Up 1.8 %

Shares of CDLX stock opened at $3.44 on Friday. The company has a market capitalization of $174.83 million, a price-to-earnings ratio of -0.56 and a beta of 1.61. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm has a 50-day moving average price of $3.73 and a 200 day moving average price of $6.25. Cardlytics has a twelve month low of $2.89 and a twelve month high of $20.52.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The business had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. During the same quarter in the previous year, the business posted ($0.26) earnings per share. The company’s revenue was down 15.1% on a year-over-year basis. Research analysts forecast that Cardlytics will post -1.52 earnings per share for the current fiscal year.

Insider Transactions at Cardlytics

In other Cardlytics news, CFO Alexis Desieno sold 25,118 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the transaction, the chief financial officer now owns 116,481 shares in the company, valued at $399,529.83. The trade was a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This trade represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,691 shares of company stock worth $237,767. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cardlytics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Canton Hathaway LLC raised its stake in shares of Cardlytics by 95.7% during the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after purchasing an additional 2,200 shares during the period. Atom Investors LP purchased a new stake in Cardlytics during the 3rd quarter worth $33,000. XTX Topco Ltd purchased a new stake in Cardlytics during the 2nd quarter worth $107,000. Banco Santander S.A. acquired a new position in Cardlytics in the 1st quarter worth $199,000. Finally, SG Americas Securities LLC purchased a new position in Cardlytics in the 3rd quarter valued at about $45,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.